Literature DB >> 2593768

Distribution and molecular forms of glucagon-like peptide in the dog.

K Suda1, H Takahashi, N Fukase, H Manaka, M Tominaga, H Sasaki.   

Abstract

Using glucagon-like peptide-1 N-terminus and C-terminus directed antisera, we investigated concentration and molecular forms of GLP-1 immunoreactivity (IR) in extracts of various tissues of the dog. GLP-1 IR measured with C-terminus-directed antiserum R2337 (GLP-1 IR-CT) was high in the ileum, appendix, jejunum, colon, and gastric fundus and body. GLP-1 IR measured with N-terminus-directed antiserum R1043 (GLP-1 IR-NT) was high only in the pancreas, and gastric fundus and body. Only GLP-1 IR-CT was found in the hypothalamus, thalamus and medulla oblongata. No immunoreactive materials were detected in the liver, spleen and kidney. Gel-filtration with Sephadex G-50 showed two peaks of both GLP-1 IR-CT and GLP-1 IR-NT, at 10kd and at the position of GLP-1 (1-36 amide) in the pancreatic extract, and one peak at 10kd in the stomach extract. Ileal extracts showed 3 peaks of GLP-1 IR-CT at 10kd, at the position of GLP-1(1-36 amide) and GLP-1(7-36 amide), respectively, but GLP-1 IR-NT was coeluted with GLP-1(1-36 amide). Hypothalamic extracts showed a single peak at the position of GLP-1(7-36 amide). These results suggest that processing of preproglucagon differs in different organs, and that the main GLP-1-related products are a large molecular form and GLP-1(1-36 amide) or GLP-1(1-37) in the pancreas, and GLP-1(7-36 amide) or GLP-1 (7-37) in the ileum and hypothalamus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2593768     DOI: 10.1016/0024-3205(89)90519-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  A potential and novel therapy for obesity: "appendix" electrical stimulation in dogs.

Authors:  Yong Lei; Jiande D Z Chen
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

Review 2.  Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?

Authors:  Lin Li
Journal:  Neurosci Bull       Date:  2007-01       Impact factor: 5.203

3.  Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones.

Authors:  V Ionut; K Hucking; I F Liberty; R N Bergman
Journal:  Diabetologia       Date:  2005-04-14       Impact factor: 10.122

Review 4.  Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide.

Authors:  E Blázquez; E Alvarez; M Navarro; I Roncero; F Rodríguez-Fonseca; J A Chowen; J A Zueco
Journal:  Mol Neurobiol       Date:  1998-10       Impact factor: 5.590

Review 5.  Glucagon-like peptide-1, a new hormone of the entero-insular axis.

Authors:  C Orskov
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

6.  Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.

Authors:  N Fukase; H Manaka; K Sugiyama; H Takahashi; M Igarashi; M Daimon; K Yamatani; M Tominaga; H Sasaki
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

7.  Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy.

Authors:  Li Lin
Journal:  Clin Med Pathol       Date:  2008-07-28

8.  Glucagon-like peptide-1 analogues: An overview.

Authors:  Vishal Gupta
Journal:  Indian J Endocrinol Metab       Date:  2013-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.